CARDURA XL Rx
Generic Name and Formulations:
Doxazosin (as mesylate) 4mg, 8mg; ext-rel tabs.
Indications for CARDURA XL:
Swallow whole. Take w. breakfast. Initially 4mg once daily; may titrate after 3–4 weeks to max 8mg/day. If therapy is stopped for several days, restart at 4mg once daily. Switching from Cardura to Cardura XL: initially 4mg once daily; do not take final evening dose of Cardura. Concomitant PDE-5 inhibitors: initiate at lowest dose.
Severe hepatic impairment: not recommended. Mild or moderate hepatic impairment. Syncope. Symptomatic hypotension. Exclude prostate cancer. Severe GI narrowing. Coronary insufficiency; discontinue if angina pectoris appears or worsen. Cataract surgery (intraoperative floppy iris syndrome possible). Elderly. Pregnancy, nursing mothers: not indicated for females.
Caution with strong CYP3A4 inhibitors (eg, atanazavir, clarithromycin, indinavir, ketoconazole, itraconazole, nefazodone, others). Additive hypotension with concomitant PDE-5 inhibitors.
Headache, dizziness, asthenia, hypotension, dyspnea, postural hypotension, somnolence, respiratory or urinary tract infections; rare: priapism.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds